Personalising medicine: feasibility and future implications from a payers' perspective

Brian Godman, Isabel Frost, Richard Harrington, AE Finlayson

Research output: Contribution to journalArticle

Abstract

There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.
LanguageEnglish
Pages61-65
Number of pages5
JournalJournal of Rare Diseases Research and Treatment
Publication statusAccepted/In press - 25 Nov 2016

Fingerprint

Precision Medicine
Patient Care
Orphaned Children
Microbiota
Financial Management
Rare Diseases
Routine Diagnostic Tests
Drug Resistance
Biomarkers
Costs and Cost Analysis
Health
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • patient response
  • patient treatment
  • drug resistance

Cite this

@article{ba1943c93e9d4483be5bc228d5150543,
title = "Personalising medicine: feasibility and future implications from a payers' perspective",
abstract = "There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.",
keywords = "patient response, patient treatment, drug resistance",
author = "Brian Godman and Isabel Frost and Richard Harrington and AE Finlayson",
year = "2016",
month = "11",
day = "25",
language = "English",
pages = "61--65",
journal = "Journal of Rare Diseases Research and Treatment",

}

Personalising medicine : feasibility and future implications from a payers' perspective. / Godman, Brian; Frost, Isabel; Harrington, Richard; Finlayson, AE.

In: Journal of Rare Diseases Research and Treatment, 25.11.2016, p. 61-65.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Personalising medicine

T2 - Journal of Rare Diseases Research and Treatment

AU - Godman, Brian

AU - Frost, Isabel

AU - Harrington, Richard

AU - Finlayson, AE

PY - 2016/11/25

Y1 - 2016/11/25

N2 - There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.

AB - There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.

KW - patient response

KW - patient treatment

KW - drug resistance

UR - http://www.rarediseasesjournal.com

M3 - Article

SP - 61

EP - 65

JO - Journal of Rare Diseases Research and Treatment

JF - Journal of Rare Diseases Research and Treatment

ER -